Kevin W. Chamberlin, PharmD

This new treatment option copackages 3 drugs for optimal treatment.

The FDA has approved finerenone (Kerendia, Bayer) for the treatment of adults with chronic kidney disease (CKD) associated with type 2 diabetes.

Ser/dex is a dexmethylphenidate-based prodrug for ADHD in patients 6 years and older.

A new drug review for vericiguat, indicated for heart failure, reports efficacy and safety data.

An overview of the use of satralizumab-mwge (Enspryng; Genentech) in neuromyelitis optica spectrum disorder (NMOSD).

Oliceridine (Olinvyk; Trevena, Inc) is an intravenous opioid agonist indicated in adults for management of acute severe pain in a hospital or controlled clinical setting.

On June 25, 2020, fenfluramine (Fintepla) was approved for the treatment of seizures associated with Dravet syndrome in patients 2 years and older.

Levodopa/carbidopa is currently the gold standard for controlling motor symptoms associated with Parkinson disease.

Indicated as part of a three-drug oral combination.

Cariprazine demonstrated greater improvement on the MADRS.

FDA approves lofexidine for opioid withdrawal symptoms.

The FDA recently approved cannabidiol oral solution to treat seizures.

Vabomere combines a carbapenem and a beta-lactamase inhibitor as a treatment for complicated urinary tract infections.

CSL Behring's Kcentra is is currently the only 4-factor PCC available in the United States.